Trombosit indeksleri: infantil hemanjiom tedavisinin izlenmesinde yeni bir araç

Abstract

Amaçlar: İnfantil hemanjiyom (İH), çocukluk çağında en sık görülen benign vasküler tümördür. Tanı, tedavi kararı ve tedavinin izlenmesi zordur. Bu çalışmanın amacı trombosit (PLT) indekslerinin IH tedavisinin takibinde bir belirteç olarak kullanımını araştırmaktır. Yöntemler: Çalışmaya …….. Üniversitesi Pediatrik Hematoloji ve Onkoloji Anabilim Dalı polikliniğine başvuran ve takip edilen hastalar dahil edildi. Hastaların demografik verileri, tedavi sonuçları ve belirli zaman noktalarındaki PLT indeksleri retrospektif olarak analiz edildi. Sonuçlar: PLT, ortalama trombosit hacmi (MPV) ve trombosit dağılım genişliği (PDW) yatışta, tedavinin birinci ve ikinci aylarından sonra, tedavi tamamlandığında ve etkilenen hastalarda rebound atakları sırasında ölçüldü. Başvurudaki seviyeleri tedavinin birinci ayıyla karşılaştırıldığında PLT, PDW ve MPV değerlerinde genel bir azalma kaydedildi. Beklendiği gibi, tüm trombosit indeksleri bu dönemde düşüş eğilimi gösterdi. Ek olarak, tedavinin birinci ve ikinci ayları arasında PDW ve MPV'de istatistiksel olarak anlamlı farklılıklar belirlendi. Sonuç: IH hastalarının %15'ine kadarı komplikasyonlar nedeniyle tedaviye ihtiyaç duyabilir. Bu çalışma, PLT, PDW ve MPV değerlerinin tedavi yanıtını değerlendirmek ve klinik karar almaya rehberlik etmek için değerli biyobelirteçler olarak hizmet edebileceğini vurgulamaktadır.

Keywords

• İnfantil hemanjiyom
• trombosit indeksleri
• propranolol tedavisi

Platelet indices: a new tool for monitoring infantile hemangioma treatment

Abstract

Aims: Infantile hemangioma (IH) is the most common benign vascular tumor in childhood. Diagnosis, treatment decisionmaking, and monitoring of the treatment are challenging. This study aims to investigate the utilization of platelet (PLT) indices as a marker in the follow-up of IH treatment. Methods: The patients who were admitted and followed up in the outpatient clinic of Erciyes University Department of Pediatric Hematology and Oncology were enrolled in the study. The demographical data, treatment results, and PLT indices of the patients at certain time points were analyzed retrospectively. PLT, mean platelet volume (MPV), and platelet distribution width (PDW) were measured at various time points: upon admission, after the first and second months of treatment, at treatment completion, and during rebound episodes in affected patients. Results: A general decrease in PLT, PDW, and MPV values was noted when comparing admission levels to the first month of treatment. The mean PLT count was 452.680/mm3 at admission, it decreased to 405.900/mm3 at the 1st month, 376.600/mm3 at the 2nd month and 359.900/mm3 at the end of treatment (p: 0,002). Besides MPV was evaluated, it was observed that while the mean was 10.43 fl at the time of admission, it decreased to 9.51 fl in the following months and the decline was statistically significant with a p value of 0,031. Lastly, regarding the mean PDW values, a decline was detected once again from 11.34 % to 10.2 % between the admission time and termination of the treatment with a statistically significant p value of <0.001. Conclusion: Up to 15% of IH patients may require treatment due to complications. This study highlights that PLT, PDW, and MPV values can serve as valuable biomarkers for assessing treatment response and guiding clinical decision-making.

Keywords

• Infantile hemangioma
• platelet indices
• propranolol treatment

References

1. Eisenstein KA. Infantile hemangiomas: a review and future opportunities. Mo Med. 2023;120(1):49-52.
2. Hemangioma Investigator Group, Haggstrom AN, Drolet BA, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007;150(3):291-294. doi:10.1016/j.jpeds.2006.12.003
3. Cazeau C, Blei F, Gonzáles Hermosa MDRF, et al. Burden of infantile hemangioma on family: an international observational cross-sectional study. Pediatr Dermatol. 2017;34(3):295-302. doi:10.1111/pde.13133
4. Surlis T, De Sa Reilly H, Sadlier M, Nelson J. Infantile haemangiomas. BMJ. 2022;378:e068734. doi:10.1136/bmj-2021-068734
5. Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1): e20183475. doi:10.1542/peds.2018-3475
6. Broeks IJ, Hermans DJ, Dassel AC, van der Vleuten CJ, van Beynum IM. Propranolol treatment in life-threatening airway hemangiomas: a case series and review of literature. Int J Pediatr Otorhinolaryngol. 2013; 77(11):1791-1800. doi:10.1016/j.ijporl.2013.08.011
7. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128-140. doi:10.1542/peds.2012-1691
8. Nazemian S, Sharif S, Childers ELB. Infantile hemangioma: a common lesion in a vulnerable population. Int J Environ Res Public Health. 2023; 20(8):5585. doi:10.3390/ijerph20085585

9. Jacobs AH. Strawberry hemangiomas; the natural history of the untreated lesion. Calif Med. 1957;86(1):8-10.
10. Surlis T, De Sa Reilly H, Sadlier M, Nelson J. Infantile haemangiomas. BMJ. 2022;378:e068734. doi:10.1136/bmj-2021-068734
11. Gnarra M, Behr G, Kitajewski A, et al. History of the infantile hepatic hemangioma: from imaging to generating a differential diagnosis. World J Clin Pediatr. 2016;5(3):273-280. doi:10.5409/wjcp.v5.i3.273
12. Tiemann L, Hein S. Infantile hemangioma: a review of current pharmacotherapy treatment and practice pearls. J Pediatr Pharmacol Ther. 2020;25(7):586-599. doi:10.5863/1551-6776-25.7.586
13. McGee P, Miller S, Black C, Hoey S. Propranolol for infantile haemangioma: a review of current dosing regime in a regional paediatric hospital. Ulster Med J. 2013;82(1):16-20.
14. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3):e423-e431. doi: 10.1542/peds.2008-3458
15. Greenberger S, Bischoff J. Pathogenesis of infantile haemangioma. Br J Dermatol. 2013;169(1):12-19. doi:10.1111/bjd.12435
16. Phung TL, Hochman M. Pathogenesis of infantile hemangioma. Facial Plast Surg. 2012;28(6):554-562. doi:10.1055/s-0032-1329930
17. Eroglu N, Sen HS, Kar YD, Pektas A, Eker I. Can propranolol affect platelet indices in infantile hemangioma? J Pediatr Hematol Oncol. 2023;45(7):e899-e903. doi:10.1097/MPH.0000000000002683
18. Weksler BB, Gillick M, Pink J. Effect of propranolol on platelet function. Blood. 1977;49(2):185-196. doi:10.1182/blood.V49.2.185.185
19. Ring ME, Corrigan JJ Jr, Fenster PE. Antiplatelet effects of oral diltiazem, propranolol, and their combination. Br J Clin Pharmacol. 1987;24(5):615-620. doi:10.1111/j.1365-2125.1987.tb03220.x
20. Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med. 2012;44(8):805-816. doi:10.3109/ 07853890.2011.653391
21. Şen HS, Yalçın B, Canpınar H, Ocak S, Akyüz C. Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol. Turk J Pediatr. 2020;62(6):979-985. doi:10.24953/turkjped.2020.06.009